Presentation at EANS 2021 Congress

Invex Therapeutics Limited │ ABN 29 632 145 334│ Level 1, 38 Rowland St, Subiaco, Perth WA 6008 │ ASX / Media Release 8 October 2021 Presentation at EANS 2021 Congress Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a clinical -stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure (ICP), today announces a poster presentation titled “ A randomised con trolled trial of the GLP -1 receptor agonist exenatide in idiopathic intracranial hypertension ” was presented at the European Association of Neurosurgical Societies (EANS) Neurosurgery in Translation 2021 Virtual Congress. EANS is both an independent federation of European national neurosurgical societies and a fast - developing association of individual neurosurgeons from around the world. Dr James L. Mitchell of the Institute of Metabolism and Systems Research, University of Birmingham presented data from Invex’s Phase II Pressure Trial in Idiopathic Intracranial Hypertension (IIH), with the study authors concluding “ Exenatide reduced ICP acutely and after chronic dosing. GLP -1R agonists represent a new approach to treat IIH.” A copy of the poster abstract will be available following the EANS C ongress at: https://eanscongress.org/ - ENDS - This release dated 8 October 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary. For more information, please contact: Company/Investors Dr Thomas Duthy Executive Director [email protected] +61 402 493 727 Media Margie Livingston Ignite Communications [email protected] +61 438 661 131 To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter @InvexThera_ASX Invex Therapeutics Limited │ ABN 29 632 145 334│ Level 1, 38 Rowland St, Subiaco, Perth WA 6008 │ 2 About Invex Therapeutics Ltd Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Pre sendin™. www.invextherapeutics.com. About Idiopathic Intracranial Hypertension (IIH) IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20 -30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

The release as fetched from its publisher. weblink.com.au ↗